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derived suppressor cells and regulatory T cells,
and better survival in older breast cancer patients
Jithendra Kini Bailur1, Brigitte Gueckel2, Evelyna Derhovanessian1,3 and Graham Pawelec1*Abstract
Introduction: Breast cancer is one of the most common cancers among women. Its incidence is increasing in
many countries and a higher number of older women are now being diagnosed with the disease. Immune
parameters are implicated in disease progression, and the frequencies of both myeloid-derived suppressor cells
(MDSCs) and regulatory T cells (Tregs), associated with tumour burden, have been suggested to be indicators of
poor prognosis in cases of metastatic breast cancer.
Methods: Here, we have assessed the frequency of peripheral Tregs and MDSCs in relation to in vitro T cell
responses to Her2 antigen in 40 untreated breast cancer patients 65 to 87 years of age at diagnosis.
Results: The five-year survival rate of patients who mounted a CD8+ T cell response to Her2 peptides and had a
lower frequency of Lin−CD14+HLA-DR−MDSCs was 100% compared to only 38% in patients without Her2-reactive
CD8+ T cells and with higher frequencies of MDSCs (P = 0.03). Patients who lacked a CD8 response to Her2 tended
to have higher frequencies of MDSCs. Similarly, patients who lacked a CD8 response to Her2 and had higher
frequencies of CD4+Foxp3+CD127lowCD25+ Tregs had only 50% survival compared to the 100% survival of patients
who did mount a CD8 response and had lower frequencies of Tregs (P = 0.03). A similar trend was observed for
activated (CD4+CD45RA−Foxp3hi) but not resting Tregs (CD4+CD45RA+FoxP3+). This survival advantage was
observed in both metastatic and non-metastatic patients.
Conclusions: Our data demonstrate a negative role of both MDSCs and Tregs in the prognosis of breast cancer
patients, the mechanism of which might be through dampening favourable CD8+ T cell immune responses to
tumour-associated antigens.Introduction
Breast cancer is one of the most common cancers among
women worldwide, the incidence of which increases with
age [1]. Surgery, chemotherapy and radiotherapy remain
the mainstays of treatment, but currently there is great
interest in exploiting the patient’s own immune system to
control cancer. However, immunity in older people tends
to be less effective than in the young, a phenomenon
termed ‘immunosenescence’ [2]. This could compromise* Correspondence: graham.pawelec@uni-tuebingen.de
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to destroy their tumour. Recent results using immuno-
modulatory antibodies are highly encouraging in melan-
oma, lung cancer and several other tumour types [3-6] but
there is thus far rather little experience in older patients or
those with breast cancer. Antibodies directed to cytotoxic
T-lymphocyte associated protein 4 (CTLA-4), programmed
cell death protein 1 (PD-1) or programmed death ligand 1
(PDL-1) now coming into widespread use are commonly
perceived as ‘taking the brakes off ’ immunity. However,
this strategy will only be effective if an immune response
is potentially present. In melanoma, we have shown that
the presence of peripheral T cells responding to certain
tumour-associated antigens (TAAs) predicts extendedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(Her-2) is an important TAA in breast cancer, which can
be targeted by antibodies and T cells [8,9]. Although a nor-
mal self-protein, it is often overexpressed in breast and
ovarian cancers and can thus be selectively targeted by
antibody; there are also a number of anti-Her2 therapies
in early phases of clinical trials that seek to elicit T cell re-
sponses in cancer patients [10]. For successful immuno-
surveillance and exploitation of such host anti-tumour
reactivity in immunotherapy, it is likely important for the
patient to be able to neutralize or decrease the activity of
immunosuppressive cells, both T regulatory cells (Tregs)
and myeloid-derived suppressor cells (MDSCs). These
have been implicated in negating anti-tumour activity in
several types of cancers [11-13]. Thus, tumour infiltration
by Tregs has been associated with poor clinical outcome
not only in breast cancer, but several other cancers as well
[14-17]. It is also possible to extract clinically relevant in-
formation on Tregs by analyzing peripheral blood. For
routine and repeated monitoring, a blood test rather than
resected tumour or tumour biopsies is required. Analysis
of cells in suspension obtained from the blood also allows
the application of polychromatic flow cytometry for better
characterization of cell types than is possible with immu-
nohistochemistry in tissue sections, and avoids digesting
the tissue to obtain infiltrating cells. Depending on the co-
expression of additional markers like CD45RA, Tregs can
be distinguished into activated and resting (aTregs and
rTregs). On stimulation of rTregs, forkhead box P3
(FoxP3) expression is upregulated, leading to the differen-
tiation and proliferation of aTreg. The frequencies and ra-
tios of aTreg and rTreg are known to change in some
diseases and can provide additional information on the
likely suppressive milieu [18].
The other main suppressive cells, the MDSCs, are a
heterogeneous population of immature dendritic cells,
macrophages and granulocytes [19-21] exerting suppres-
sive activity by several different mechanisms [22,23].
High levels of MDSCs have been negatively associated
with survival in different cancers [24-26] including in
one breast cancer study.
As the immune system in older people is generally im-
paired, this may make them more susceptible to infec-
tions, and possibly to cancer. They tend to respond poorly
to vaccination against infectious agents such as influenza
[27]. The implication would be that any anti-cancer im-
munomodulatory therapy relying on an intact immune
system in older people might be compromised by immu-
nosenescence, due to increased suppression and decreased
effector function. Here, we investigated whether measur-
able immune parameters could be found even in older
breast cancer patients that were predictive of survival and
might provide insights into anti-cancer mechanisms under
the most challenging circumstances. We conclude that thepresence of T cell reactivity to Her2, related to lower levels
of immunosuppressive Tregs and MDSCs, correlates posi-
tively with survival of older patients with breast cancer,
despite their potentially immunosenescent state.
Methods
Patients
Blood samples from 40 patients were collected at the
University Hospital Tübingen (Women’s Clinic) from
March to November 2009. Blood was drawn upon first
diagnosis, prior to any treatment or surgery. Peripheral
blood mononuclear cells (PBMCs) were isolated using
standard Ficoll-Hypaque gradient and cryopreserved for
experimental purposes. Approval for this study was
obtained from the Institutional Ethics Committee of
University Clinic Tuebingen (71/2009BO2) and a waiver
of informed consent was granted for this study. The pa-
tients were at different tumour stages grouped according
to tumour size (T), nodal status (N) and metastasis (M)
(Table 1).
Detection of tumour-associated antigen-reactive-T-cells
T cell responses to Her2 (extra- and intracellular do-
mains) were measured after a 12-day in vitro culture.
On Day 0 the PBMCs were thawed and resuspended in
X-Vivo 15 supplemented with interleukin (IL)-4 (5 ng/ml:
Sandoz, Basel, Switzerland) and IL-7 (5 ng/ml: Sterling-
Winthrop, New York, NY, USA). On Day 1, mixtures of
overlapping peptides (15-mers with an overlap of 11
amino acids) covering the entire sequence of Her2
(PepMix: JPT Technologies, Berlin, Germany) were added,
at a concentration of 1 μg/ml. 1 × 106 cells were used for
the analysis of T cell reactivity. IL-2 (40 U/ml: Chiron Beh-
ring GmbH, Marburg, Germany) was added on Day 3.
On Day 12 cultured T cells were harvested and restimu-
lated (0.4 to 0.5 × 106 cells/well) with Her2 PepMix at a
concentration of 1 μg/ml or left unstimulated as a nega-
tive control for 12 hours. As a positive control, cells
were also stimulated with influenza nucleoprotein (NP)
and matrix protein (M1) Pepmixes. Golgi-plug (BD
Biosciences, Franklin Lakes, NJ, USA) was added at
1 μl/ml to all cultures. After the incubation period,
cells were harvested, washed and incubated with
Gamunex™ (Talecris Biotherapeutics, Clayton, NC, USA)
and ethidium monoazide (EMA, MoBiTec GmbH, Goet-
tingen, Germany) as a marker for dead cells, followed by
fixation and permeabilization with Cytofix/Cytoperm (BD
Biosciences). The cells were then stained with the fol-
lowing monoclonal antibodies: CD3-Pacific Orange
(Invitrogen, Carlsbad, CA, USA), CD4-Pacific Blue,
tumour necrosis factor (TNF)-fluorescein isothiocyanate
(FITC), IL-2-Alexa Fluor-700, IL-5-phycoerythrin (PE)
(BioLegend, San Diego, CA, USA), CD8-allophycocyanin-
indocyanine 7 (APC-Cy7), interferon gamma (IFN-γ)-
Table 1 Characteristics of the breast cancer patients
Clinicopathological parameters (n = 40)
Age range (years) 65-87
Median age (years) 75



























ER status unknown 1
PR+ 31
PR status unknown 1
Her2: 2+ 4




Adj endocrine therapy 30
ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal
growth factor receptor 2; Adj, adjuvant.
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IL-10-allophycocyanin (APC) (Miltenyi Biotech, Bergisch
Gladbach, Germany) and IL-17-peridinin-chlorophyll
protein-cyanine 5.5 (PerCP-Cy5.5) (eBioscience, San
Diego, CA, USA). Cells were immediately measured usinga BD-LSR II flow cytometer using the FACSDiva software
(BD Biosciences).
Phenotypic analysis of Tregs and MDSCs
For characterization of Tregs, PBMCs were incubated
first with EMA and Gamunex™, followed by indirect
staining for CD3 with a primary CD3 antibody (OKT3
supernatant) and a Pacific Orange-conjugated secondary
antibody (Invitrogen). After blocking the non-specific
binding of the secondary antibody with mouse serum
(Merck Millipore, Darmstadt, Germany), cells were
directly stained with CD4-Pacific Blue, CD45RA-Alexa
Fluor-700, CD8-peridinin-chlorophyll protein (PerCP),
CD279-PerCP-Cy5.5, CD127-Alexa Fluor-647 (BioLegend)
and CD25-APC-Cy7 (BD Biosciences). The cells were then
fixed and permeabilized using the human FoxP3 kit (Bio-
Legend) and the cells were stained for intracellular FoxP3
using a PE-conjugated antibody (BioLegend) according to
the manufacturer’s instructions.
For characterization of MDSCs, PBMCs were stained
with a cocktail of lineage (Lin) markers (CD3, CD19,
CD56)-Brilliant Violet 605 (BioLegend, BD Biosciences),
CD14-Brilliant Violet 711 (BioLegend), CD45-V500,
CD15-FITC, HLA-DR PerCP-Cy5.5, CD11b APC-Cy7,
CD33 Alexa Fluor-700 (BD Biosciences), and CD124-
APC (R&D Systems, Minneapolis, MN, USA). All sam-
ples were measured using a BD LSRII (BD Biosciences)
immediately after staining.
Flow cytometry data analysis
Data were analyzed using FlowJo software (Tree Star
Inc., Ashland, OR, USA). Initially, the duplicates were
removed by using an FSC-area versus FSC-height/width
plot. These initial steps were done for all flow cytometry
datasets. The viable and CD3+ cells were gated to plot
CD4+ and CD8+ cells (FACS plots are shown in Figure
S1 in Additional file 1). To detect cytokine-producing
cells, the unstimulated (negative) control was compared
with the stimulated samples and the response considered
positive when at least one cytokine was produced by the
stimulated sample, defined as an at least twofold in-
crease in the peptide-stimulated culture compared to the
unstimulated negative control, as established as a rele-
vant cutoff in earlier studies in melanoma patients [7].
To analyze the Tregs within viable cells, FoxP3+ cells were
gated from total CD4+ cells followed by gating of CD127lo and
CD25+ cells. The activated Tregs (CD4+CD45RA−FoxP3hi)
and resting Tregs (CD4+CD45RA+FoxP3+) were gated by
plotting CD45RA against FoxP3 according to a published
model [18]. CD4+ cells were the parental population for
the analysis of different Treg subsets (gating strategy
shown in Figure S2 in Additional file 2).
To analyze the MDSCs within viable cells, CD45+ cells
were gated followed by gating CD14+ cells from the Lin(−)
Figure 1 Survival analysis for CD8-Res vs. CD8-NR to Her2.
Survival analysis for the patients (n = 38) grouped according to CD8+
T cell response to Her2 (CD8-Res) and no CD8+ T cell response to Her2
(CD8-NR). Her2, human epidermal growth factor receptor 2.
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the CD14+ population defined as MDSC-1 (Lin−CD14+
HLA-DR−). The MDSC-2 population (Lin−CD14+CD124+)
comprising CD124+ cells was gated from the CD14+ cells by
plotting CD124+ against it. CD45+ cells were considered
as the parental population for calculating the frequency of
different MDSC subsets (gating strategy shown in Figure S3
in Additional file 3).
Statistical analysis
To compare independent groups, chi-square tests and
Mann-Whitney U tests were performed. Kaplan-Meier
analysis was performed for the survival estimates.
GraphPad Prism 6 was used to perform this analysis
(GraphPad Software Inc., San Diego, CA, USA). Multi-
variate Cox analysis was performed using SPSS version
20.0 (IBM Corp, Armonk, NY, USA). A value of P <0.05
was considered statistically significant.
Results
T cell responses to Her2
T cell responses to mixtures of Her2 peptides were ob-
served in the majority of older breast cancer patients
tested (97%, n = 38). Fluorescence-activated cell sorting
(FACS) data from a representative donor are shown in
Figure S1 in Additional file 1. Most patients exhibited
CD4+ T cell responses to Her2 (32/38, 87%), whereas
CD8+ T cell responses were detected in only 18 patients
(47%) irrespective of whether they had a CD4+ T cell
response. Of all the patients, five had only a CD8+ T cell
response to Her2 and no CD4+ T cell response. Because
most patients possessed CD4+ T cells responding to
Her2, these responses would be unlikely to be associated
with longer or shorter survival. Thus, the patients were
grouped according to whether they mounted a CD8+
T cell response (irrespective of whether they had a CD4+
T cell response). All patients’ T cells responded to influ-
enza peptides, the positive control (data not shown).
CD8 response to Her2 correlates with overall survival
Kaplan-Meier survival analysis showed that patients
who mounted a CD8+ T cell response against Her2 had
a significantly better survival (log-rank test: P = 0.03)
compared to the patients who did not. There was only
17% mortality in the group of patients with a CD8 T cell
response to Her2 when compared to the patients with-
out a CD8+ T cell response, where mortality was 45%.
The five-year overall survival rate was 82% for patients
with a CD8+ T cell response against Her2 compared
with 52% for those without a CD8+ T cell response.
Further, having no CD8+ T cell response to Her2 had
an early impact on survival as well (Gehan-Breslow test:
P = 0.02) (Figure 1). Also, five patients who had only a
CD8+ T cell response (no CD4+ T cell response) toHer2 had 100% survival compared to the others (data
not shown).
When only metastatic patients (n = 6) were considered
for Kaplan-Meier analysis according to their response to
Her2, those who lacked a CD8+ T cell response (n = 5)
had only 25% survival rate compared to the one patient
with a CD8+ T cell response still alive at five years (data
not shown). Further, the Kaplan-Meier analysis of meta-
static and non-metastatic patients showed significantly a
better survival for the latter (log rank test: P = 0.03) as ex-
pected. Also, patients who received adjuvant radiotherapy
had better survival (log rank test: P = 0.001) compared to
those who did not (Table 2). Multivariate Cox analysis was
performed for 37 patients considering all significant
factors (Model 1). It was observed that having no CD8+
T cell response to Her-2 had an independent negative
impact on survival (P = 0.014) along with no adjuvant
radiotherapy (P = 0.001). Next, we performed Cox analysis
(Model 2) without considering adjuvant radiotherapy
and no association was observed for Her-2 responders
(P = 0.052) and metastasis status (P = 0.12) (Table 3).
Associations of tumour characteristics with T cell
responses to Her-2
Further, the fractions of patients with CD8+ T cell re-
sponses to Her-2 were analyzed for their correlation with
different prognostic factors. We found that the proportion
of CD8+ T cell responders decreased with increasing
tumour stage (Figure 2). There were significantly higher
proportions of CD8+ T cell responders in patients with tu-
mours at stage 0 and 1 compared to patients with tumours
at stage 3 and 4 (P = 0.01). No difference was observed
when patients with stage 2 tumours were compared with
those with stage 0 and 1 tumours and with those in stage
3 and 4 (Figure 2). There was no difference observed in
the percentage of CD8+ T cell responders in patients with
Table 2 Survival analysis according to the Kaplan-Meier
method
Overall survival rate
Factor N1 % dead (5 years) % 95% CI P
Metastasis 0.03
No 33 28 72 0.01-0.8
Yes 6 50 40 1.1-65.6
Estrogen receptor 0.3
No 9 44 55 0.5-8.1
Yes 30 23 75 0.1-1.9
Progesterone receptor 0.7
No 12 25 72 0.2-2.9
Yes 27 29 69 0.3-4.3
Her2 status 0.3
Neg 34 26 72 0.05-2.8
Pos 4 50 50 0.3-17.9
Chemotherapy 0.2
Yes 3 0 100 0.04-2.3
No 37 12 65 0.4-21.07
Radiotherapy 0.003
Yes 27 19 81 0.03-0.5
No 13 54 37 1.9-28.6
Hormonal therapy 0.3
Yes 30 27 72 0.1-1.9
No 10 40 53 0.5-8.2
CD8 response to Her2 0.03
Yes 18 17 82 0.09-0.9
No 20 45 52 1.07-10.4
MDSC-1 0.7
<median 18 28 70 0.2-2.6
≥median 19 32 66 0.3-4.01
MDSC-2 0.8
<median 18 33 66 0.3-3.7
≥median 19 26 70 0.2-2.8
Results of survival analysis according to Kaplan-Meier method and P values
from Mantex-Cox (log rank) test.
Table 3 Multivariate Cox analysis
Model 1
Prognostic factor N1 % dead Hazard ratio (95% CI) P
CD8 response to Her-2 0.27 (0.07-1.01) 0.014
Yes 18 17
No 20 45
Metastasis 2.76 (0.65-11.64) 0.16
No 32 28
Yes 6 50




Prognostic factor N1 % dead Hazard ratio (95% CI) P
CD8 response to Her2 0.27 (0.07-1.01) 0.052
Yes 18 17
No 20 45
Metastasis 2.8 (0.7-10.7) 0.12
No 32 28
Yes 6 50
1Data for a few patients are missing. Multivariate Cox analysis was performed,
where CD8 response to Her2, metastasis and radiotherapy is considered
(Model 1), which shows that having no CD8+ T cell response to Her2 has an
independent impact on survival (P = 0.014) along with patients who did not
receive radiotherapy (P = 0.001) on five-year survival, whereas, in Model 2 no
association was observed for no CD8+ T cell responders to Her2 and metastasis.
CI, confidence interval; Her2, human epidermal growth factor receptor 2.
p =0.01
Figure 2 Distribution of CD8+ T cell responders to Her-2
according to tumour stage. Percentage of CD8+ T cell responders
to Her-2 are significantly higher in patients with tumour stage 0,1
(T 0,1) compared to the patients with tumour stage 3,4 (T 3,4). Her2,
human epidermal growth factor receptor 2.
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progesterone receptor, or triple-negative breast cancer or
metastasis (data not shown).
Tumour stage and immunosuppressive subsets
We showed above that CD8+ T cell responses to Her2
correlated with tumour stage and patient survival. Thus,
we next correlated the frequency of Tregs (n = 30) and
MDSCs (n = 37), the two immunosuppressive types, with
the tumour stage. For the two MDSC types (MDSC-1
and MDSC-2 as described in the Methods) there was nodifference observed between different tumour stages in
this cohort. Although there was also no difference
observed for the classical Tregs between the tumour
stages, a trend was observed for increasing levels of acti-
vated Tregs and for the ratio of activated/resting Tregs
with increasing tumour stage. There was no difference
Bailur et al. Breast Cancer Research  (2015) 17:34 Page 6 of 11observed for FoxP3-expressing CD4+ T cells with regard
to tumour stage. However, a significant difference was
observed for activated Tregs (P = 0.04) and for the ratio
of activated/resting Tregs (P = 0.01) when patients were
stratified into one group for tumour stage 0 and 1 and
then compared to a second group with tumour stage 2,
3 and 4 (data not shown).
Overall survival and immunosuppressive subsets
Kaplan-Meier survival analysis was performed for the
immunosuppressive subsets in patients with lower than
median and greater than or equal to the median levels of
MDSC types (Figure 3A and B) and Tregs (Figure 3C,D,
E and F). From the survival analysis it was observed that
none of the immunosuppressive subtypes of Tregs and
MDSCs correlated with survival, although there was a
consistent trend throughout for lower than median
levels of Tregs and MDSCs to correlate with better sur-
vival in this prospective study.Figure 3 Survival analysis of immunosuppressive subtypes. Kaplan-Me
(higher than or equal to median) levels of (A) MDSC-1 (n = 37), (B) MDSC-2
Tregs (n = 30), (E) Tregs (n = 30) and (F) CD4+/FoxP3+ T cells (n = 30), show
Tregs, regulatory T cells.Cellular responses to Her2 and different
immunosuppressive subsets
Here, we sought to determine if the ability to mount a
CD8+ T cell response to Her-2 was associated with the
frequency of different immunosuppressive subsets. For
this, the patients were grouped according to the pres-
ence or absence of CD8+ T cell response to Her-2, and
the frequency of Tregs and MDSC types was compared
between the two groups.
We found that patients with no CD8+ T cell response
to Her-2 tended to have higher proportions of MDSC-1
(P = 0.09) but no difference was observed for MDSC-2
(Figure 4A and B). No significant differences were
observed for Tregs, resting Tregs (data not shown) or
FoxP3-expressing CD4+ T cells (Figure 4C and D). How-
ever, patients lacking a CD8+ T cell response to Her-2
had significantly higher proportions of activated Tregs
(P = 0.01) and the ratio of activated/resting Tregs (P =
0.04) was significantly higher as well (Figure 4E and F).ier analysis of patients with low (lower than median) versus high
(n = 37), (C) activated Tregs (n = 30), (D) ratio of activated/resting
ed no significant difference. MDSC, myeloid-derived suppressor cells;







Figure 4 Percentage of immunosuppressive subtypes in CD8-Res and CD8-NR. Patients with CD8+ T cell response to Her-2 had low levels of
(A) MDSC-1 (P = 0.09) compared to no CD8+ T cell response. No difference was observed in case of (B) MDSC-2, (C) Tregs and (D) CD4+/FoxP3+
T-cells. The levels of (E) activated Tregs and (F) ratio of activated/resting Tregs was significantly lower in patients with a CD8+ T cell response to Her-2.
Her-2, human epidermal growth factor receptor 2; MDSC, myeloid-derived suppressor cells; Tregs, regulatory T cells.
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response to Her-2 and low levels of immunosuppressive
subsets
Kaplan-Meier survival analysis for non-metastatic
(tumour stage 0,1,2,3) patients showed that those who
mounted a CD8+ T cell response to Her-2 and also pos-
sessed low levels (<median) of MDSC-1 had better sur-
vival (log-rank test: P = 0.01) than patients with no CD8
T cell response to Her-2 and high levels of MDSC-1
(Figure 5A). There was also an early impact on survival
of patients with high levels (≥median) of MDSC-1 and
without a CD8+ T cell response to Her-2 (Gehan
Breslow test: P = 0.02) (Figure 5A). Strikingly, the overall
survival rate was 100% in patients with low MDSC-1
levels but with CD8+ T cell responses to Her-2 com-
pared to only 38% in patients with high levels of MDSC-
1 and no CD8 + T cell response to Her-2. For MDSC-2
type, there was no significant difference observed,
although the patients with low levels of MDSC-2 and aCD8+ T cell response to Her-2 had a 75% survival rate
compared to 38% in patients with high levels of MDSC-2
and no CD8 T cell response to Her-2 (log-rank test:
P = 0.1) (Figure 5B). Interestingly, the survival advantage
was retained when all patients (metastatic and non-
metastatic, data not shown) were considered together,
where those with low MDSC-1 levels and CD8+ T cell
responses to Her-2 had 100% survival compared to
53% of patients with high levels of MDSCs and no CD8+
T cell response (log-rank test: P = 0.03, Gehan Breslow
test: P = 0.04). For the MDSC-2 subset, there was no
significant difference observed for survival (log-rank
test: P = 0.2) although the patients with low levels of
MDSC-2 and CD8 + T cell responses to Her-2 had 75%
survival compared to 53% survival in patients with
high levels of MDSC-2 and no CD8+ T-cell response
to Her-2.
Regarding regulatory T cell subsets, non-metastatic pa-






Figure 5 Survival analysis for patients with CD8-Res and CD8-NR to Her-2 according the levels of immunosuppressive subtypes.
Survival of non-metastatic patients with low levels (lower than median) (A) MDSC-1 and CD8+ T cell response to Her-2 had significantly a better
survival (P = 0.01) compared to the patients with high (higher than or equal to median) levels of MDSC-1 and no CD8+ T cell response to Her-2
(n = 15). No differences were observed in case of (B) MDSC-2 for non-metastatic patients (n = 15). Survival for non-metastatic patients with CD8+
T cell response to Her-2 and low (lower than median) levels of (C) Tregs (n = 12), (D) activated Tregs (n = 12), (E) ratio of activated/resting Tregs
(n = 12) and (F) CD4+/FoxP3+ T cells (n = 12) tended to have a better survival compared to the patients with no CD8+ T cell response to Her-2 and
high (higher than or equal to median) levels of regulatory T cell subtypes. Her-2, human epidermal growth factor receptor 2; MDSC, myeloid-derived
suppressor cells; Tregs, regulatory T cells.
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Log-rank test: P = 0.1). This was also the case for activated
Tregs (Figure 5D. Log-rank test: P = 0.1), the activated/
resting Treg ratio (Figure 5E. Log-rank test: P = 0.1) and
the FoxP3+/CD4+ T cell subset ratio (Figure 5F. Log-rank
test: P = 0.1). Although not statistically significant, this
trend has thus been observed for all the subtypes of Tregs.
Further, when all the patients (metastatic and non-
metastatic, data not shown) were considered together in
the Kaplan-Meier analysis, those with low levels of Tregs
and with a CD8+ T-cell response to Her-2 had a signifi-
cantly better survival (Log-rank test: P = 0.03) comparedto those without a CD8+ T cell response to Her-2 and
with high levels of Tregs. Also, a significant early impact
on survival was observed in patients with high levels of
Tregs and no CD8 T cell responses (Gehan-Breslow test:
P = 0.03). The overall survival rate was 100% in patients
with low levels of Tregs and a CD8+ T cell response to
Her-2, compared to 50% in patients with high levels of
Tregs and no CD8+ T cell response. Similar results were
observed in patients with low levels of activated Tregs
(Log-rank test: P = 0.06) and FoxP3-expressing CD4+ T
cells (Log-rank test: P = 0.06) compared to those with no
CD8+ T cell response to Her-2 and high levels of activated
Bailur et al. Breast Cancer Research  (2015) 17:34 Page 9 of 11Tregs and FoxP3-expressing CD4+ T cells. Although
patients with a CD8+ T cell response to Her-2 and low
levels of resting Tregs tended to have poorer survival
compared to patients lacking CD8+ T cell response to
Her-2 and with low levels of resting Tregs (P = 0.09),
patients with a CD8+ T cell response to Her-2 and a low
activated/resting Treg ratio did have better survival
(Log-rank test: P = 0.03, Gehan-Breslow test: P = 0.04)
than those with no CD8+ T-cell response to Her-2 and a
high ratio of activated/resting Tregs. The data were also
analyzed by first determining the levels of MDSCs
and Tregs and then considering the Her-2 reactive CD8+
T cells. No correlations were observed.Discussion
We previously reported that the presence of T cells
responding in vitro to NY-ESO-1 and/or Melan A pep-
tides was associated with longer survival of late-stage
melanoma patients [6]. Melanoma patients tend to be
relatively young, so we wished to determine whether these
earlier findings were relevant in other tumours mostly oc-
curring in older people whose immune systems may already
be compromised by age (‘immunosenescence’). In the
present study, we asked whether responses of older
breast cancer patients’ T cells to Her-2 peptides were
similarly associated with survival and whether the nature
of the responding T cells influenced any such associ-
ation. We found functional circulating Her-2-reactive
T cells in 97% of the patients, almost all of whom pos-
sessed antigen-reactive CD4+ T cells. However, only
about half of these patients also possessed CD8+ Her-2-
reactive T cells, and their presence did correlate posi-
tively with better five-year overall survival. Interestingly,
the survival rate of patients possessing solely CD8+
T cells responsive to Her2 had 100% survival compared to
worse survival of those who also had CD4+ T cell re-
sponses. This finding emphasizes the benefit of possessing
circulating CD8+ anti-TAA cells and implicates CD4+
T cells as potential suppressors of such responses (for ex-
ample as CD4+ Tregs). Thus, we identified one parameter
negatively influencing the proportion of patients with an
anti-Her-2 CD8+ T cell response as increasing tumour
stage, but another as the presence of suppressive cell
types in the blood, both Tregs and MDSCs. An associ-
ation with MDSCs, but not with Tregs, was also seen
in our studies on melanoma [23].
These findings support an important role for Her2-
specific T cells in controlling tumour cells in vivo. Although
most of the patients had tumours with low expression of
Her2 (Her2-0,1,2), T cell responses were present in almost
all. These results are consistent with studies indicating the
benefit of Her2 vaccine in Her2-negative (low expression)
patients as well [28-30].According to the Kaplan-Meier analysis, as expected,
metastatic patients had poor survival relative to non-
metastatic patients. Nonetheless, this variable did not
have any independent impact on survival when consid-
ered together with CD8+ T cell responses in Model 1
and Model 2 of the Cox multivariate analysis. However,
a CD8+ T cell response to Her2 had an independent
positive impact in Model 1 of the Cox analysis. Also, a
strong trend was observed in Model 2 for CD8+ T cell
responses to Her2.
In our previous study on stage IV melanoma, levels of
one of the MDSC subtypes above the median correlated
negatively with survival [24], but in the current study we
did not observe any direct survival disadvantage for pa-
tients with such high levels of MDSCs. This difference
might be due to potentially different roles of the various
suppressive cell types in different cancers; as mentioned
by Montero et al. [31] there are different MDSC sub-
types that are associated with different type of cancers,
in addition to different Treg associations. Nonetheless,
when MDSC data were not examined in isolation, but
together with other factors, a highly favourable survival
advantage (P = 0.01) was observed in non-metastatic
patients with a CD8+ T cell response to Her2 who
also had low levels (lower than median) of MDSC-1
(Lin-CD14 +HLA-DR-). These patients had a 100% sur-
vival rate compared to only 38% in patients with no
CD8+ T cell response to Her2 and high levels of MDSC-
1. These differences were still significant when metastatic
patients were included in the analysis as well (P = 0.03),
with a survival rate of 100% for patients with CD8+ T cell
response to Her2 and low levels of MDSC-1 compared to
the 53% survival rate in patients with no CD8+ T cell
response to Her2 and high levels of MDSC-1. Thus, the
prognostic impact of the MDSCs was not limited only to
non-metastatic breast cancer.
Earlier studies on breast cancer showed increased
levels of one of the MDSC subtypes at higher tumour
stage [31], but in the present study, no such differences
were observed. This might be because of our small co-
hort of patients; however, we observed that the per-
centage of CD8+ T cell responders decreased with
increasing tumour stage, consistent with a possible role
of immunosuppressive cells in these patients. In line
with this, the levels of MDSC-1 were higher in patients
with no CD8+ T cell response to Her2, which might
indicate the altering capacity and suppressive role
played by MDSCs on CD8+ T cells as described in
earlier studies [32-34,11,24].
In contrast, the frequencies of Treg subtypes did not
correlate with survival, although in other types of can-
cers like ovarian and renal cell carcinoma, high levels of
Tregs have been reported to correlate with poor survival
[35,12]. Nonetheless, the non-metastatic patients with a
Bailur et al. Breast Cancer Research  (2015) 17:34 Page 10 of 11CD8+ T cell response to Her2 and low levels of Tregs,
aTregs, ratio of a/r Tregs or FoxP3+/CD4+ T cells showed
a strong trend towards better survival: a 100% survival rate
was seen for lower levels of all the regulatory Tcell subtypes
compared to patients with high levels of regulatory T cell
subtypes and no CD8+ T cell response to Her2. These sur-
vival differences were significant for Tregs (P = 0.03) with
a survival rate of 100% in patients with low levels of Tregs
and a CD8+ T cell response to Her2. Similar results were
observed for the ratio of a/rTregs (P = 0.03), aTregs (P =
0.06) and CD4+/FoxP3+ T cells (P = 0.06) when all pa-
tients were considered in the analysis. Also, the levels
of aTregs and the ratio of a/rTregs were higher in pa-
tients with no CD8+ T cell response to Her2, which
again suggests a suppressive role played by the regula-
tory T cell subtypes in this cohort of patients. Previous
studies have already shown that increased levels of
Tregs do have suppressive effects on T cells in cancer
patients [36].
This study emphasizes the clinical relevance of the in-
dividual’s circulating CD8+ TAA-reactive T cells, which
confer a significant survival advantage. In particular, a
combination of reactivity to Her2 antigens and lower
circulating suppressive cells translates to better survival
of the older breast cancer patient. These findings have
several important implications: (1) they emphasize that
despite an immune system potentially compromised by
immunosenescence, older patients retain the ability to
mount clinically relevant anti-cancer responses against
Her2, which could be exploited in immunotherapy;
(2) they suggest that one mechanism dampening benefi-
cial anti-TAA responses is the presence of suppressive
cells, which could be targeted therapeutically to enhance
anti-cancer activity.Conclusions
The results from the present study indicate that while
levels of MDSCs and Tregs alone might not be bio-
markers for survival, CD8+ T cell responses to Her2,
which do correlate with longer survival, are likely to be
affected by these immunosuppressive cells. This may
result from the effects of these cells during the analytic
in vitro culture used here, but also suggests a potentially
similar mechanism in vivo. To the best of our know-
ledge, this is the first study on older breast cancer pa-
tients showing an advantage of having a CD8+ T cell
response to Her2 and at the same time showing the pos-
sible negative role played by MDSCs and Tregs. Cancer
vaccines targeting Her2 together with the application of
strategies to deplete Tregs and MDSCs might thus pro-
vide clinical benefit even in older breast cancer patients
whose immune systems are generally considered to be
compromised by the ageing process.Additional files
Additional file 1: Figure S1. CD4+ and CD8+ T-cell response to
Her-2. The duplicates were removed by using a FSC-area versus FSC-height/
width plot. The viable and CD3+ cells were gated earlier to plot CD4+ and
CD8+ cells. A representative plot of control and Her-2 stimulated cytokine
(for example: IFN-γ) producing cells for CD4+ T-cells and CD8+ T-cells
are shown.
Additional file 2: Figure S2. Gating strategy for regulatory T-cell
subtypes. The duplicates were removed by using a FSC-area versus
FSC-height/width plot. The viable and CD3+ cells were gated to plot
CD4+ and CD8+ cells. FoxP3+ cells were gated from total CD4+ cells
followed by gating of CD127lo and CD25+ cells. The activated Tregs
(CD4+CD45−FoxP3hi) and resting Tregs (CD4+CD45RA+FoxP3+) were
gated by plotting CD45RA against FoxP3+ cells. Also, FoxP3+ cells were
gated from CD4+ T-cells (CD4 + FoxP3+).
Additional file 3: Figure S3. Gating strategy for MDSC subtypes. The
duplicates were removed by using a FSC-area versus FSC-height/width plot.
Viable and CD45+ cells were gated initially followed by gating CD14+ cells
from the Lin(−) population. The HLA-DR(−) population was gated from
CD14+ population defined as MDSC-1 (Lin−CD14+HLA-DR−). The MDSC-2
population (Lin−CD14+CD124+) comprising CD124+ cells were gated from
the CD14+ cells by plotting CD124+ against it.
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